{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:13:21Z","timestamp":1778897601193,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rpth.2025.103322","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:28:22Z","timestamp":1767025702000},"page":"103322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, tolerability, pharmacokinetics, and pharmacodynamics of KN060, a humanized anti-FXI\/FXIa dual-domain antibody, following single ascending doses in healthy Chinese subjects"],"prefix":"10.1016","volume":"10","author":[{"given":"Jie","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanrong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanpin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5930-586X","authenticated-orcid":false,"given":"Guoping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103322_bib1","series-title":"Guidelines for the prevention and treatment of thrombotic diseases in","year":"2018"},{"key":"10.1016\/j.rpth.2025.103322_bib2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","article-title":"Thrombosis: a major contributor to global disease burden","volume":"34","author":"Raskob","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2025.103322_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000506396","article-title":"Global, regional and country-specific burden of ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage: a systematic analysis of the Global Burden of Disease Study 2017","volume":"54","author":"Krishnamurthi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.rpth.2025.103322_bib4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2025.103322_bib5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/ATVBAHA.124.320151","article-title":"Global health burden of venous thromboembolism","volume":"44","author":"Wendelboe","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2025.103322_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pharmthera.2010.12.007","article-title":"The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism","volume":"130","author":"Mavrakanas","year":"2011","journal-title":"Pharmacol Ther"},{"issue":"6 Suppl","key":"10.1016\/j.rpth.2025.103322_bib7","first-page":"969S","article-title":"Addenda","volume":"133","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2025.103322_bib8","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/heartjnl-2015-307489","article-title":"Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis","volume":"101","author":"Caldeira","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.rpth.2025.103322_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(15)60245-8","article-title":"Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs","volume":"386","author":"Verheugt","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103322_bib10","article-title":"Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery","volume":"11","author":"Amaral","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rpth.2025.103322_bib11","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1016\/j.asjsur.2024.02.113","article-title":"The safety and efficacy of NOACs versus LMWH for thromboprophylaxis after THA or TKA: a systematic review and meta-analysis","volume":"47","author":"Ding","year":"2024","journal-title":"Asian J Surg"},{"key":"10.1016\/j.rpth.2025.103322_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","article-title":"An update on factor XI structure and function","volume":"161","author":"Mohammed","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103322_bib13","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/ATVBAHA.116.306925","article-title":"Factor XI as a therapeutic target","volume":"36","author":"Gailani","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2025.103322_bib14","first-page":"19","article-title":"Factors XI and XII as targets for new anticoagulants","volume":"4","author":"Weitz","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.rpth.2025.103322_bib15","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103322_bib16","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103322_bib17","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103322_bib18","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1111\/j.1538-7836.2006.02093.x","article-title":"Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice","volume":"4","author":"Wang","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103322_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2020.100696","article-title":"Turning up to eleven: factor XI inhibitors as novel agents to maximize safety and maintain efficacy in thromboembolic disease","volume":"46","author":"Cave","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.rpth.2025.103322_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103322_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2025.103322_bib22","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"key":"10.1016\/j.rpth.2025.103322_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103322_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103322_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2024.108137","article-title":"CPhaMAS: an online platform for pharmacokinetic data analysis based on optimized parameter fitting algorithm","volume":"248","author":"Kuang","year":"2024","journal-title":"Comput Methods Programs Biomed"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:53:14Z","timestamp":1778896394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925006466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2475037925006466"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103322","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of KN060, a humanized anti-FXI\/FXIa dual-domain antibody, following single ascending doses in healthy Chinese subjects","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103322","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103322"}}